{'fraction_non_alphanumeric': 0.036561264822134384, 'fraction_numerical': 0.0266798418972332, 'mean_word_length': 5.291925465838509, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Q‐Switched Ruby Laser Treatment for Postsclerotherapy Hyperpigmentation

Background. One of the most common adverse sequelae of sclerotherapy is cutaneous hyperpigmentation. Objective. We used the Q‐switched ruby laser to treat postsclerotherapy hyperpigmentation. Methods. Eight patients developed pigmentation lasting more than 1 year (1–2 years on average) after sclerotherapy treatment for reticular and telangiectatic veins in the legs ranging in size from 0.2 to 4 mm in diameter. All patients were treated with a Q‐switched ruby laser at 694 nm, 4 mm beam size, and fluence range of 5.6–10.5 J/cm2. Results. Ninety‐two percent of lesions lightened after treatment. There was significant (75–100%) resolution of hyperpigmentation in 58% of treated areas, 25% improvement in 33% of treated areas, and no improvement in the remaining areas. Conclusion. Our impression is that given a choice of lasers, the Q‐switched ruby laser provides the greatest efficacy for treating postsclerotherapy hyperpigmentation.